| APALUTAMIDE |
Erlyand® |
Janssen-Cilag Pty Ltd |
Prostate cancer |
Jul 2022 |
Recommended |
| RUXOLITINIB |
Jakavi® |
Novartis Pharmaceuticals Australia Pty Limited |
Graft versus host disease |
Jul 2022 |
Recommended |
| OLAPARIB |
Lynparza® |
AstraZeneca Pty Ltd |
Ovarian cancer |
Jul 2022 |
Not Recommended |
| USTEKINUMAB |
Stelara® |
Janssen-Cilag Pty Ltd |
Severe Crohn disease Severe chronic plaque psoriasis |
Jul 2022 |
Recommended |
| NATALIZUMAB |
Tysabri® |
Biogen Australia Pty Ltd |
Multiple sclerosis |
Jul 2022 |
Recommended |
| CEMIPLIMAB |
Libtayo® |
sanofi-aventis Australia Pty Ltd |
Cervical cancer |
Jul 2022 |
Not Applicable |
| AZACITIDINE |
Onureg® |
Celgene Pty Limited |
Acute myeloid leukaemia |
Jul 2022 |
Not Recommended |
| ADALIMUMAB |
Yuflyma® |
Celltrion Healthcare Australia Pty Ltd |
Severe Crohn disease Moderate to severe ulcerative colitis Severe active juvenile
idiopathic arthritis Complex refractory fistulising Crohn disease Severe active rheumatoid
arthritis Severe psoriatic arthritis Ankylosing spondylitis Severe chronic plaque
psoriasis Moderate to severe hidradenitis suppurativa |
Jul 2022 |
Recommended |
| NIVOLUMAB |
Opdivo® |
Bristol-Myers Squibb Australia Pty Ltd |
Urothelial carcinoma |
Jul 2022 |
Not Recommended |
| ROMOSOZUMAB |
Evenity® |
Amgen Australia Pty Limited |
Osteoporosis |
Jul 2022 |
Not Recommended |
| BECLOMETASONE WITH FORMOTEROL |
Fostair® 200/6 |
Chiesi Australia Pty Ltd |
Asthma |
Jul 2022 |
Recommended |
| VOSORITIDE |
Voxzogo® |
BioMarin Pharmaceutical Australia Pty Ltd |
Achondroplasia |
Jul 2022 |
Not Recommended |
| PEMBROLIZUMAB |
Keytruda® |
Merck Sharp & Dohme (Australia) Pty Ltd |
Urothelial cancer Colorectal cancer Primary Mediastinal B-cell Lymphoma Classical
Hodgkin Lymphoma |
Jul 2022 |
Recommended |
| ATEZOLIZUMAB |
Tecentriq® |
Roche Products Pty Ltd |
Non-small cell lung cancer |
Jul 2022 |
Recommended |
| LEUPRORELIN ACETATE |
Eligard® 6 month |
Mundipharma Pty Limited |
Central precocious puberty |
Jul 2022 |
Recommended |
| ANIFROLUMAB |
Saphnelo® |
AstraZeneca Pty Ltd |
Systemic lupus erythematosus |
Jul 2022 |
Not Recommended |
| TEZEPELUMAB |
Tezspire® |
AstraZeneca Pty Ltd |
Asthma |
Jul 2022 |
Not Applicable |
| FINERENONE |
Kerendia® |
Bayer Australia Ltd |
Diabetic kidney disease |
Jul 2022 |
Not Recommended |
| PROGESTERONE |
Cyclogest® |
Gedeon Richter Australia Pty Ltd |
Infertility |
Jul 2022 |
Recommended |
| EPTINEZUMAB |
Vyepti® |
Lundbeck Australia Pty Ltd |
Chronic migraine |
Jul 2022 |
Recommended |
| ASCIMINIB |
Scemblix® |
Novartis Pharmaceuticals Australia Pty Limited |
Chronic myeloid leukaemia |
Jul 2022 |
Not Recommended |
| EVOLOCUMAB |
Repatha® |
Amgen Australia Pty Limited |
Hypercholesterolaemia |
Jul 2022 |
Recommended |
| HUMAN MENOPAUSAL GONADOTROPHIN |
Menopur® 600 Menopur® 1200 |
Ferring Pharmaceuticals Pty Limited |
Assisted Reproductive Technology |
Jul 2022 |
Recommended |
| DAUNORUBICIN WITH CYTARABINE |
Vyxeos® |
Jazz Pharmaceuticals ANZ Pty Ltd |
Acute myeloid leukemia |
Jul 2022 |
Not Applicable |
| PEGVALIASE |
Palynziq® |
BioMarin Pharmaceutical Australia Pty Ltd |
Phenylketonuria |
Jul 2022 |
Not Recommended |
| TRASTUZUMAB DERUXTECAN |
Enhertu® |
AstraZeneca Pty Ltd |
Breast cancer |
Jul 2022 |
Not Recommended |
| UPADACITINIB |
Rinvoq® |
AbbVie Pty Ltd |
Ulcerative colitis |
Jul 2022 |
Deferred |
| MIDAZOLAM |
Zyamis® |
Clinect Pty Ltd |
Epilepsy |
Jul 2022 |
Not Recommended |
| USTEKINUMAB |
Stelara® |
Janssen-Cilag Pty Ltd |
Ulcerative colitis |
Jul 2022 |
Recommended |
| RELATLIMAB WITH NIVOLUMAB |
Opdualag® |
Bristol-Myers Squibb Australia Pty Ltd |
Melanoma |
Jul 2022 |
Not Recommended |
| DUPILUMAB |
Dupixent® |
sanofi-aventis Australia Pty Ltd |
Chronic severe atopic dermatitis |
Jul 2022 |
Not Recommended |
| RISANKIZUMAB |
Skyrizi® |
AbbVie Pty Ltd |
Crohn disease |
Jul 2022 |
Deferred |
| ESKETAMINE |
Spravato® |
Janssen-Cilag Pty Ltd |
Depression |
Jul 2022 |
Not Recommended |
| NIVOLUMAB |
Opdivo® |
Bristol-Myers Squibb Australia Pty Ltd |
Oesophageal carcinoma or gastroesophageal junction carcinoma |
Jul 2022 |
Not Recommended |
| POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL |
Optix® |
Petrus Pharmaceuticals Pty Ltd |
Severe dry eye syndrome, including Sjogren's syndrome |
Jul 2022 |
Recommended |
| SAPROPTERIN |
Kuvan® |
BioMarin Pharmaceutical Australia Pty Ltd |
Phenylketonuria |
Jul 2022 |
Recommended |
| CANNABIDIOL |
Epidyolex® |
Chiesi Australia Pty Ltd |
Lennox-Gastaut syndrome |
Jul 2022 |
Not Recommended |
| VERICIGUAT |
Verquvo® |
Bayer Australia Ltd |
Chronic heart failure |
Jul 2022 |
Recommended |
| PEGCETACOPLAN |
Empaveli™ |
Swedish Orphan Biovitrum Pty Ltd |
Paroxysmal nocturnal haemoglobinuria |
Jul 2022 |
Recommended |